Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has realigned its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler Biopharma will withdraw from the field of cell and gene therapy, ceasing operations at its Stevenage, UK site, and increase its focus on biologics.

This decision is part of the company’s strategy to adapt to evolving market conditions and client needs, prioritize sustainable growth, and drive innovation.

“As an innovation leader, we continuously evaluate new approaches to meet the needs of our clients and their patients,” explained Benedikt von Braunmühl, CEO of Rentschler Biopharma. “The cell and gene therapy market has experienced slower-than-expected growth, with demand across the industry not meeting our expectations. Following a comprehensive strategic review, we are focusing our efforts on areas where we see the greatest demand and potential to create value sustainably.”

In recent years, Rentschler Biopharma has made significant investments to further strengthen its global capabilities and support long-term growth. In 2024, Rentschler Biopharma announced its largest single investment to date at its headquarters in Laupheim, to enhance production efficiency and upgrade the site capabilities. Earlier that year, the new production line, in Milford, MA in the U.S., became fully operational with four new 2,000 L single-use bioreactors.